Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Morphine-6-glucuronide disposition in renal impairment

M H Hanna1, F D'Costa, S J Peat

  • 1Department of Anaesthesia, King's College Hospital, London.

British Journal of Anaesthesia
|May 1, 1993
PubMed
Summary

Morphine-6-glucuronide (M6G) is cleared faster in kidney transplant patients than in those with renal impairment. Peritoneal dialysis had minimal impact on M6G levels in patients with chronic renal failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Tests of Cognition using a Computerized Touch-Sensitive Tablet, Eye Tracking, and Functional Magnetic Resonance Imaging.

Journal of visualized experiments : JoVE·2026
Same author

Advancing next-generation sequencing access: aspirations for next-generation sequencing policy and patient access in Hong Kong.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

Freiburg Neuropathology Case Conference : Headache, Mental Confusion and Mild Hemiparesis in a 68-year-old Patient.

Clinical neuroradiology·2023
Same author

Technical report: surgical preparation of human brain tissue for clinical and basic research.

Acta neurochirurgica·2023
Same author

Correction to: Multifamily groups for patients with schizophrenia: an exploratory randomised controlled trial in Bosnia and Herzegovina.

Social psychiatry and psychiatric epidemiology·2022
Same author

Multifamily groups for patients with schizophrenia: an exploratory randomised controlled trial in Bosnia and Herzegovina.

Social psychiatry and psychiatric epidemiology·2022

Area of Science:

  • Pharmacology
  • Nephrology
  • Anesthesiology

Background:

  • Morphine-6-glucuronide (M6G) is a potent opioid analgesic.
  • Its pharmacokinetics can be significantly altered in patients with renal dysfunction.
  • Understanding M6G disposition is crucial for safe pain management in renally impaired patients.

Purpose of the Study:

  • To investigate the pharmacokinetics of intravenous M6G in patients with chronic renal failure (CRF) compared to kidney transplant recipients.
  • To assess the impact of peritoneal dialysis on M6G elimination in CRF patients.

Main Methods:

  • A single intravenous dose of M6G (30 µg/kg) was administered to 12 dialysis-dependent CRF patients, 6 non-dialyzed CRF patients, and 6 kidney transplant recipients.
  • Serum M6G concentrations were measured up to 12 hours post-administration using high-performance liquid chromatography.

Related Experiment Videos

  • Pharmacokinetic parameters including elimination half-life and clearance were calculated for each group.

    • Main Results:

    • M6G elimination half-life was significantly shorter in transplanted patients (2.14 h) compared to non-dialyzed CRF patients (27.10 h) and dialyzed CRF patients (17.33 h).
    • M6G clearance was significantly greater in transplanted patients (96.0 ml/min) versus non-dialyzed (10.57 ml/min) and dialyzed CRF patients (14.3 ml/min).
    • Peritoneal dialysis initiated 6 hours post-M6G administration showed a limited effect on M6G disposition compared to non-dialyzed CRF patients.

    Conclusions:

    • Kidney transplant recipients exhibit significantly more rapid M6G clearance than patients with chronic renal failure.
    • M6G is eliminated slowly in patients with renal impairment, necessitating careful dosing.
    • Peritoneal dialysis offers minimal benefit in accelerating M6G elimination in the studied timeframe.